Literature DB >> 24973276

N-Polybenzylated alicyclic 1,2-diamines: cytotoxicity and G1 phase arrest in cancer cell line.

Antonio Caldarelli1, Valeria De Biasio, Giovanni B Giovenzana, Gianpiero Mastronardo, Roberto Negri.   

Abstract

Cytotoxicity in the μM range was observed in cancer cell lines treated with N,N,N',N'-tetrabenzyl-4,5-diamino-2-cyclopentenone. Cell cycle analysis on HeLa cells showed a clear G1 phase arrest. A preliminary SAR on structural analogs was performed in order to identify the pharmacophores.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24973276     DOI： 10.1007/s11030-014-9519-5

Source DB:  PubMed          Journal:  Mol Divers        ISSN： 1381-1991            Impact factor:   2.943


  23 in total

1.  Site and mechanism of growth inhibition by prostaglandins. IV. Effect of cyclopentenone prostaglandins on cell cycle progression of G1-enriched HeLa S3 cells.

Authors:  K Ohno; T Sakai; M Fukushima; S Narumiya; M Fujiwara
Journal:  J Pharmacol Exp Ther       Date:  1988-04       Impact factor: 4.030

2.  Leishmanicidal and trypanocidal activities of 2-aminocyclohexanol and 1,2-cyclohexanediamine derivatives.

Authors:  Oscar Rebollo; Esther del Olmo; Grace Ruiz; José L López-Pérez; Alberto Giménez; Arturo San Feliciano
Journal:  Bioorg Med Chem Lett       Date:  2007-11-01       Impact factor: 2.823

3.  Chemical and biological studies on a series of novel (trans-(1R,2R)-, trans-(1S,2S)-, and cis-1,2-diaminocyclohexane)platinum(IV) carboxylate complexes.

Authors:  A R Khokhar; S al-Baker; S Shamsuddin; Z H Siddik
Journal:  J Med Chem       Date:  1997-01-03       Impact factor: 7.446

4.  Synthesis and Antimicrobial Activity of N,N'-Bis(2-hydroxylbenzyl)-1,2-ethanediamine Derivatives.

Authors:  Musiliyu A Musa; M Omar F Khan; Arden Aspedon; John S Cooperwood
Journal:  Lett Drug Des Discov       Date:  2010-03       Impact factor: 1.150

5.  Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.

Authors:  L R Kelland; G Abel; M J McKeage; M Jones; P M Goddard; M Valenti; B A Murrer; K R Harrap
Journal:  Cancer Res       Date:  1993-06-01       Impact factor: 12.701

6.  Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.

Authors:  R J McRipley; P E Burns-Horwitz; P M Czerniak; R J Diamond; M A Diamond; J L Miller; R J Page; D L Dexter; S F Chen; J H Sun
Journal:  Cancer Res       Date:  1994-01-01       Impact factor: 12.701

7.  Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.

Authors:  M Drees; W A Dengler; T Roth; H Labonte; J Mayo; L Malspeis; M Grever; E A Sausville; H H Fiebig
Journal:  Clin Cancer Res       Date:  1997-02       Impact factor: 12.531

8.  Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.

Authors:  N Raje; T Hideshima; S Mukherjee; M Raab; S Vallet; S Chhetri; D Cirstea; S Pozzi; C Mitsiades; M Rooney; T Kiziltepe; K Podar; Y Okawa; H Ikeda; R Carrasco; P G Richardson; D Chauhan; N C Munshi; S Sharma; H Parikh; B Chabner; D Scadden; K C Anderson
Journal:  Leukemia       Date:  2009-01-08       Impact factor: 11.528

9.  A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors.

Authors:  Elisabeth I Heath; Keith Bible; Robert E Martell; Daniel C Adelman; Patricia M Lorusso
Journal:  Invest New Drugs       Date:  2007-10-16       Impact factor: 3.850

10.  In vitro antileishmanial, trypanocidal, and Mammalian cell activities of diverse n,n' -dihetaryl substituted diamines and related compounds.

Authors:  Sandra M Leal; Diego F Amado; Vladimir V Kouznetsov; Patricia Escobar
Journal:  Sci Pharm       Date:  2012-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.